Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

BACKGROUND: Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance. METHODS: Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or complete r...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheler, Jennifer, Yelensky, Roman, Falchook, Gerald, Kim, Kevin B, Hwu, Patrick, Tsimberidou, Apostolia M, Stephens, Philip J, Hong, David, Cronin, Maureen T, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232/
https://www.ncbi.nlm.nih.gov/pubmed/25886620
http://dx.doi.org/10.1186/s12885-015-1029-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340232/
https://www.ncbi.nlm.nih.gov/pubmed/25886620
http://dx.doi.org/10.1186/s12885-015-1029-z

Ejemplares similares